Rubitecan

Rubitecan (RFS 2000), a Camptothecin derivative, is an orally active topoisomerase I inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells[1][2][3].

Product Specifications

CAS Number

[91421-42-0]

Product Name Alternative

RFS 2000; 9-Nitrocamptothecin

UNSPSC

12352005

Hazard Statement

H301

Target

Topoisomerase

Type

Natural Products

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rubitecan.html

Concentration

10mM

Purity

99.23

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C([N+]([O-])=O)C=CC=C5N=C4C3=C2)=O

Molecular Formula

C20H15N3O6

Molecular Weight

393.35

Precautions

H301

References & Citations

[1]Burris HA 3rd, et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist. 2005 Mar;10 (3) :183-90.|[2]Rubitecan: 9-NC, 9-Nitro-20 (S) -camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000. Drugs R D. 2004;5 (5) :305-11.|[3]Rubitecan|[4]Xia M, et al. Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther. 2013 Jul;14 (7) :638-47.